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A B S T R A C T
Objectives: Rotavirus (RV) genotypes vary geographically, and this can affect vaccine effectiveness (VE).
This study investigated the genotype distribution of RV and explored VE before introducing the RV
vaccine to the national immunization programme in Vietnam.
Methods: This hospital-based surveillance study was conducted at Children’s Hospital 1, Ho Chi Minh City
in 2013–2018. Stool samples and relevant data, including vaccination history, were collected from
children aged <5 years who were hospitalized with gastroenteritis. RV was detected using enzyme
immunoassays and then genotyped. Children aged 6 months were included in the VE analysis.
Results: Overall, 5176 children were included in this study. RV was detected in 2421 children (46.8%). RV
positivity decreased over the study period and was associated with age, seasonality, location and
previous vaccination. Among 1105 RV-positive samples, G3P[8] was the most prevalent genotype (43.1%),
followed by G8P[8] (19.7%), G1P[8] (12.9%) and G2P[4] (12.9%). Overall VE was 69.7% [95% confidence
interval (CI) 53.3–80.6%] in fully vaccinated children and 58.6% (95% CI 44.1–69.4%) in children who had
received at least one dose of RV vaccine. VE was highest for G3P[8] (95% CI 75.1–84.5%) and lowest for G2P
[4] (95% CI 32.4–57.2%).
Conclusions: RV remains a major cause of acute gastroenteritis requiring hospitalization in southern
Vietnam. The RV vaccine is effective, but its effectiveness varies with RV genotype.
© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Background
Despite incidence rates decreasing worldwide, rotavirus (RV)
infection remains the leading cause of severe dehydrating
diarrhoea in infants and young children (Kotloff et al., 2013;
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evere RV gastroenteritis (RVGE) in 2018. This disease causes an
stimated 0.1 million RV-related deaths annually, the majority of
hich occur in low- and middle-income countries (LMICs) (GBD
016 Diarrhoeal Disease Collaborators, 2018).
Vaccination is one of the best strategies for reducing RV-
ssociated morbidity and mortality. Despite the recommendation
y the World Health Organization (WHO) to introduce RV
accination with a goal of 90% vaccine coverage in all countries,
nd financial support from the Global Alliance for Vaccines and
mmunization to 45 countries, the global coverage was still low at
9% in 108 countries at the end of 2019 (World Health
rganization, 2013a, 2020).
RV infection is a significant burden in Vietnam. In a cohort study
f children aged <5 years conducted in 2002 and 2003, an
stimated 820,000 outpatient consultations and 122,000–140,000
ospitalizations occurred annually, representing one of the highest
umbers of cases of hospitalization due to RVGE in South-east Asia
Anh et al., 2006). Furthermore, approximately 5500 children are
stimated to die of RVGE annually; the mortality rate is 3.6 per
000 per year, accounting for 4.3–8.5% of all deaths in children
ged <5 years (Van Man et al., 2001). The annual economic burden
s estimated to be US$3.8 million in direct costs and US$1.5 million
n indirect costs (Fischer et al., 2005). Despite the heavy burden of
V infection, RV vaccination was not included in the national
mmunization programme (NIP) in Vietnam until December 2019.
Two WHO-prequalified vaccines and one locally licensed
accine are used in Vietnam. Rotarix (GlaxoSmithKline Biologicals,
ixensart, Belgium), RotaTeq (Merck and Co., Durham, NC, USA),
nd the locally licensed Rotavin-M1 (Polyvac, Nha Trang City,
ietnam) are based on the G1P[8] strain and have efficacy similar
o that of Rotarix (Folorunso and Sebolai, 2020). These RV vaccines
re currently self-financed in Vietnam, and no data are available on
V vaccine coverage in the country. Vaccine effectiveness (VE) can
e influenced by several factors, including age, geographic location,
easonality, nutrition status, breastfeeding, co-existing enteropa-
hy, and RV genotype distribution (Trang et al., 2014; Tate et al.,
016; Folorunso and Sebolai, 2020). The RV genotype distribution
uctuates over time, and is based on the geographic area. It is often
npredictable. Moreover, some genotypes, such as G2P[4], G12P[8]
nd equine-like G3P[8], are associated with low VE (Ruiz-Palacios
t al., 2006; Ali et al., 2016; Roczo-Farkas et al., 2018; Pietsch and
iebert, 2019; Folorunso and Sebolai, 2020). Therefore, long-term
pidemiological data, including data on genotype distribution, are
ssential to establish an effective vaccine strategy (Roczo-Farkas
t al., 2018; Folorunso and Sebolai, 2020). However, in Vietnam,
enotype-specific VE according to G/P genotype has not been
valuated previously.
This study aimed to investigate RV genotype distribution
mong infants and young children hospitalized because of RVGE in
outhern Vietnam. In addition, the study explored other additional
isk factors for severe RVGE and VE based on vaccination history..
ethods
tudy design and surveillance system
This prospective hospital-based surveillance study was con-
ucted from January 2013 to December 2018 at Children’s Hospital
, Ho Chi Minh City, one of the Vietnam Rotavirus Surveillance
three or more loose stools within 24 h for <14 days, were included
in this study. Children with bloody diarrhoea, acute diarrhoea
acquired after admission, and those whose parents or guardians
did not allow their child’s enrolment were excluded from the
study. The institutional review boards of the Children's Hospital 1
and Yonsei University approved the study.
Stool specimen collection, virus detection and genotype analysis
Stool specimens were obtained from each child within 48 h of
admission for laboratory confirmation of RV. Specimens were
stored at 20 C and then sent to the Pasteur Institute, located
approximately 3 km from the hospital. Specimens were tested for
RV using a commercial enzyme immunoassay (EIA) ProSpecT
(Oxoid, Basingstoke, UK). At least 25% of EIA-positive samples
were selected at random, and used for P and G genotyping with a
semi-nested multiplex reverse-transcriptase polymerase chain
reaction using methods described previously (Nguyen et al.,
2004).
Clinical data collection
Using a standard case definition and case-based data collection
tool, the hospital staff prospectively identified children aged <5
years admitted to the hospital or emergency unit with acute
diarrhoea. Enrolled children had received routine medical care
provided by a paediatrician. Demographic data, medical history, RV
vaccination history and clinical manifestations were recorded by
questioning parents/caregivers or from the child’s vaccination
card. Information on the date of discharge, disease outcome and
discharge diagnosis was abstracted from the children’s medical
charts. All information was recorded on the standardized case
investigation form.
Severity index, seasonal/geographical distribution and general
statistics
The severity of diarrhoea at admission was assessed using the
Vesikari clinical severity scoring system (Supplementary Meth-
ods 3, see online supplementary material). Scores of >10 points,
7–10 points and <7 points indicated severe, moderate and mild
diarrhoea, respectively. As records of fever were not available in
2013 and 2014, the Vesikari score was not calculated for children
admitted in 2013 and 2014. A description of geographical
divisions is provided in Supplementary Methods 4 (see online
supplementary material). Seasons were divided into a dry season
(November–April) and a rainy season (May–October) to empha-
size seasonal trends. General statistical information regarding
Vietnam, including population size, poverty rate, under-five
mortality rate and monthly income per capita by province, was
obtained from the General Statistical Office of Vietnam (www.gso.
gov.vn) (Supplementary Table 1, see online supplementary
material).
Vaccine effectiveness
Children were included in the VE analysis if they were aged 6
months at the time of admission. RotaTeq is recommended for
routine oral administration for all infants as a three-dose series at
2, 4 and 6 months of age, and Rotarix and Rotavin-M1 areetwork hospitals in Vietnam. This hospital-based network was
stablished in 1998 and has published several country-specific
eports (Supplementary Methods 1 and 2, see online supplemen-
ary material) (Van Man et al., 2001; Nguyen et al., 2004;
odhidatta et al., 2007). Children aged <5 years whose primary
eason for hospitalization was acute watery diarrhoea, defined as27recommended as a two-dose series at 2 and 4 months of age. Cases
in whom all doses were completed were defined as ‘complete RV
vaccination’, and cases in whom all doses were not completed were
defined as ‘incomplete RV vaccination’. A dose was considered
valid if the RV infection was notified >14 days after RV vaccine
administration to allow time for the child to develop a protective8
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first analysis, children with complete immunization were included
in the vaccinee group and children with incomplete vaccination
were included in the non-vaccinee group. In the second analysis, all
children who had received at least one dose of vaccine were
included in the vaccinee group and those who had not received any
doses of vaccine were included in the non-vaccinee group. For both
methods, VE against RVGE was calculated using the following
formula: VE = (1adjusted odds ratio [OR]) 100 [%]).
Statistical analysis
Categorical variables were compared using Chi-squared test
or Wilcoxon rank-sum test, and continuous variables with
normal distributions were compared using the independent t-
test. The linear-by-linear association test was used for year-trend
analysis. Conditional logistic regression models were used to
determine the odds ratio for VE calculations. Statistical analyses
were performed using SAS Version 9.4 (SAS Inc., Cary, NC, USA), R
Version 4.0.1 (R Foundation for Statistical Computing, Vienna,




In total, 5254 children were enrolled over the study period, of
whom 5176 were included in the analysis (Figure 1). In total, 2421
children (46.8%) had RVGE, based on stool specimen findings. The
mean age at admission was 13.0  8.4 months, and >78.8% of
patients were aged between 6 and 23 months. There were no
annual or seasonal differences in patient characteristics. Only 199
children (3.9%) had received at least one dose of RV vaccine prior to
hospitalization, and 130 children (2.5%) were fully vaccinated. Of
the children with RVGE, 38.1% had severe symptoms on admission
and 9.2% required intravenous hydration. There was one fatal case
of RVGE in 2017. Other patient characteristics are described in
Table 1.
Characteristics and risk factors of rotavirus gastroenteritis
The RV-positive rate declined from 55.3% in 2013 to 43.5% in
2018 (P < 0.001, Figure 2A). The RV-positive rate increased with
age, although the absolute number of children with RVGE was
lower among children aged 24–59 months (Figure 2B). Children
with RVGE manifested more severe symptoms than children with
other forms of acute gastroenteritis (44.7% vs 32.8%; P < 0.001), and
RVGE was more prevalent in the dry season than in the rainy
season (62.3 vs 37.8%; P < 0.001; Table 1 and Figure 2C). RVGE
hospitalization was lower in children who lived in the south-
eastern region than in children who lived in the south-western
region (Table 1). The RVGE hospitalization rate in 2018 and the
major economic and sanitation indicators in the south-eastern and
south-western regions are shown in Figure 2D.
On multi-variable logistic analysis, age 6 months, earlier year
of hospitalization, dry season, residence other than the south-
eastern region, and non-vaccination were identified as risk factors
for RVGE requiring hospitalization (Table 2). Additionally, age 12
months, dry season, and non-vaccination or incomplete vaccina-
tion were risk factors for severe RVGE (Table 2).
Distribution of rotavirus genotypes
Of the RV-positive stool specimens, 1105 (45.6%) were sent for
genotype analysis. G3 was the most prevalent G genotype (46.3%)
and P[8] was the most prevalent P genotype (83.3%, Table 3). G3P
[8] was the most prevalent G/P genotype, followed by G8P[8], G1P
[8] and G2P[4]. There were major secular variations in genotype
distribution over the study period. The prevalence of G1P[8]
decreased sharply from 69.9% in 2013 to 0% in 2018, while the
prevalence of G3P[8] increased from 8.1% in 2013 to a peak of 60.7%
in 2017 and then decreased to 41.2% in 2018 (Figure 2E). The
prevalence of G8P[8] increased from 0% in 2013 to a peak of 47.2%
in 2016 and then decreased to 23.9% in 2018. The prevalence of G2P
[4] increased from 15.5% in 2013 to 37.4% in 2014, decreased to 0.4%
in 2016, and then increased to 16.3% in 2018 (Figure 2E).
G3P[8] was the most prevalent genotype in all age groups. There
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Supplementary Table 2, see online supplementary material).
otavirus vaccine effectiveness
In total, 4593 children were age-eligible for VE analysis. VE
as 69.7% [95% confidence interval (CI) 53.3–80.6%] among those
ho were fully vaccinated and 58.6% (95% CI 44.1–69.4%) among
hose who had received at least one dose of vaccine (Figure 3A,B).
E was highest among children aged 24–59 months (77.4% and
00% for those who had received at least one dose of vaccine and
hose who were fully vaccinated, respectively) and lowest among
hildren aged 12–23 months (47.6% and 55.5% for those who had
eceived at least one dose of vaccine and those who were fully
accinated, respectively); however, the differences in VE by age
ere not significant. Among the 3383 children with genotyping
ata available, the VE values for a completed schedule were 84.5%,
6.3%, 67.1% and 57.2% for G3P[8], G1P[8], G8P[8] and G2P[4],
When VE analysis was restricted to Rotarix, the most commonly
used vaccine (67.3%, 134/199), overall VE was 75.4% (95% CI 58.1–
85.5%) for a completed schedule and 71.8% (95% CI 54.9–82.4%) for
at least one dose of Rotarix (Figure 3C,D). In the analysis of Rotarix
VE by genotype, the values for a completed schedule were 100%,
85.3%, 67.7% and 46.7% for G1P[8], G3P[8], G8P[8] and G2P[4],
respectively, and those for having received at least one dose of
Rotarix were 100%, 84.2%, 65.2% and 25.3% for G1P[8], G3P[8], G8P
[8] and G2P[4], respectively. Further details on VE according to
genotype are provided in Figure 3.
Discussion
This sentinel surveillance study showed the trends in RV
infection in southern Vietnam from 2013 to 2018. Despite a
declining trend, the burden of RV infection remained high. There
was a major shift in the distribution of genotypes during the study
period: the prevalence of G3P[8] increased and the prevalence of
able 1
haracteristics of the study participants.
Characteristics Total RV-positive gastroenteritis RV-negative gastroenteritis P-value
n (%) n (%) n (%)
Age in months, mean (SD) 5176 13.0  8.4 2421 14.0  8.5 2755 12.2  8.3 <0.001
<6 572 11.1 178 7.4 394 14.3 <0.001
6–11 2169 41.9 940 38.8 1229 44.6
12–23 1911 36.9 1016 42.0 895 32.5
24–59 524 10.1 287 11.9 237 8.6
Sex 5176 2421 2755 0.93
Male 3315 64.1 1552 64.1 1763 64.0
Female 1861 36.0 869 35.9 992 36.0
Admission year 5176 2421 2755 <0.001
2013 825 15.9 456 18.8 369 13.4
2014 839 16.2 385 15.9 454 16.5
2015 827 16.0 374 15.5 453 16.4
2016 914 17.7 417 17.2 497 18.0
2017 958 18.5 435 18.0 523 19.0
2018 813 15.7 354 14.6 459 16.7
Seasonality 5176 2421 2755 <0.001
Dry season (November–April) 2667 51.5 1521 62.8 1146 41.6
Rainy season (May–October) 2509 48.5 900 37.2 1609 58.4
Geographical distribution 5176 2421 2755 <0.001
South-eastern 2750 53.1 1210 50.0 1540 55.9
South-western (Mekong River Delta) 1852 35.8 930 38.4 922 33.5
Other 574 11.1 281 11.6 293 10.6
RV vaccination before infection 5163 2415 2748 <0.001
Unvaccinated 4964 96.1 2378 98.5 2586 93.9
RV vaccinateda 199 3.9 37 1.5 162 5.9
Complete 130 2.5 18 0.7 112 4.1
Incomplete 40 0.8 11 0.5 29 1.1
Unknownb 29 0.6 8 0.3 21 0.8
Vesikari score 3356 1509 1847 <0.001
<7 (mild) 972 29.0 386 25.6 586 31.7
7–10 (moderate) 1104 32.9 448 29.7 656 35.5
11 (severe) 1280 38.1 675 44.7 605 32.8
Management
ORS (n = 5156)c 5009 97.2 2350 97.4 2659 96.9 0.26
IV hydration (n = 5156)c 438 8.5 236 9.8 202 7.4 0.002
Antimicrobials (n = 5112)c 396 7.8 150 6.3 246 9.1 <0.001
Outcome
Duration of hospitalization in days, mean (SD) 4986 4.5  4.0 2327 4.3  3.7 2659 4.6  4.2 0.11
V, rotavirus; ORS, oral rehydration solution; IV, intravenous; SD, standard deviation.
a Among them, 134 patients received Rotarix, 27 patients received RotaTeq, 10 patients received Rotavin-M1, and 28 patients received an unknown vaccine.
b Number of vaccinations had not been registered.
c Number of available data is indicated.espectively, and the VE values for having received at least one
ose of vaccine were 75.1%, 49.3%, 38.0% and 32.4% for G3P[8],
1P[8], G8P[8] and G2P[4], respectively. However, as only a
imited number of children (n = 104) had received one or more
oses of RV vaccine, the differences in VE by genotype were not
ignificant.28G1P[8] decreased. The overall VE of RV vaccines appeared high but
VE varied according by genotype. Unlike previous studies that
focused solely on genotyping and RV epidemiology, this study
provides estimates of RV VE in Vietnam during a period when RV
vaccination was self-financed (Nguyen et al., 2004; Bodhidatta
et al., 2007; Trang et al., 2014; Huyen et al., 2018).0
D.T.T. Truong, J.-M. Kang, N.T.H. Tran et al. International Journal of Infectious Diseases 105 (2021) 277–285The positive rate of RVGE in this study (46.8%) was similar to
that reported in Vietnam for 2012–2015 based on National Sentinel
Surveillance data (46.7%) (Huyen et al., 2018). This rate was higher
the rate in Vietnam was slightly lower than rates in Cambodia
(49.6%, 2010–2016), Myanmar (50.0%, 2009–2014) and Laos (52.4%,
2009–2015) (Chung et al., 2015; Angkeabos et al., 2018; Bonifacio
Figure 2. Characteristics of rotavirus gastroenteritis according to year, age, seasonality, geographic location and genotype. (A) Yearly trend of rotavirus gastroenteritis.
Positivity decreased from 55.3% in 2013 to 43.5% in 2018 (asymptotic linear-by-linear association test: Z = 4.1, P < 0.001). (B) Proportions of rotavirus gastroenteritis and
rotavirus positivity by age group. (C) Seasonality and monthly distribution of rotavirus gastroenteritis. Rotavirus gastroenteritis tended to be more prevalent in the dry season
(November–April) than the rainy season (May–October) (positivity 62.3% vs 37.8%; P < 0.001). (D) Positivity of rotavirus gastroenteritis in 2018 and the major economic and
sanitation indicators in south-west and south-east Vietnam. *Ho Chi Minh City, located in the south-eastern region. The south-eastern region had higher socio-economic
status and better sanitation (higher GDP and lower under-5 mortality rates), and had lower rotavirus gastroenteritis rates than the south-western region, which had lower
socio-economic status and poor sanitation. (E) Fluctuation in the distribution of rotavirus genotypes from 2013 to 2018. The prevalence of G1P[8] decreased sharply from
69.9% in 2013 to 0% in 2018, while G3P[8] became the most prevalent genotype from 2014 to 2018. Changes were also observed in the prevalence of G8P[8] and G2P[4]. AGE,
acute gastroenteritis.than rates reported from other Association of Southeast Asian
Nations (ASEAN) countries, such as the Philippines (38.1%, 2013–
2015), Malaysia (33.9%, 2008–2019), Indonesia (31.7%, 2015–2018)
and Thailand (29.7%, 2011–2014), and also higher than rates in
other Asian countries, including China (20.8%, 2011–2016), South
Korea (32.9%, 2012–2013) and India (45.0%, 2014–2016). However,281et al., 2018; SoukAloun et al., 2018; Theingi Win et al., 2018; Tian
et al., 2018; Athiyyah et al., 2019; Gupta et al., 2019; Tachar-
oenmuang et al., 2020).
Although the overall RV positivity rate was high, it decreased
between 2013 and 2018, and there was only one death due to RVGE
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019; Lestari et al., 2020). This has been attributed not only to an
ncrease in RV vaccine coverage but also to an increase in living
tandards due to an increase in income in LMICs (Debellut et al.,
019). Lestari et al. (2020) reported that improvements in gross
omestic product (GDP) were associated with a reduction in RV
decrease in RVGE rates. Likewise, the RVGE incidence rate was
lower in the south-eastern region, which has higher socio-
economic status including a higher GDP and lower child mortality
rate than the south-western region. These results highlight the
importance of improvement in socio-economic status along with
improved health and sanitation to reduce the incidence of RV
able 2
isk analysis for rotavirus (RV) gastroenteritis.
Variables Crude Adjusted
OR 95% CI P-value OR 95% CI P-value
All cases of gastroenteritis (n = 5163a)
Age in months
<6 Reference — — — Reference — — —
6–11 1.7 1.4 2.1 <0.001 1.7 1.4 2.1 <0.001
12–23 2.5 2.1 3.1 <0.001 2.6 2.1 3.2 <0.001
24–59 2.7 2.1 3.4 <0.001 2.6 2.0 3.4 <0.001
Sex
Male Reference — — — Reference — — —
Female 1.0 0.9 1.1 0.93 1.0 0.9 1.1 0.98
Admission year
2013 Reference — — — Reference — — —
2014 0.7 0.6 0.8 <0.001 0.7 0.5 0.8 <0.001
2015 0.7 0.6 0.8 <0.001 0.7 0.5 0.8 <0.001
2016 0.7 0.6 0.8 <0.001 0.7 0.5 0.8 <0.001
2017 0.7 0.6 0.8 <0.001 0.6 0.5 0.7 <0.001
2018 0.6 0.5 0.8 <0.001 0.5 0.4 0.6 <0.001
Seasonality
Rainy season (May–October) Reference — — — Reference — — —
Dry season (November–April) 2.4 2.1 2.7 <0.001 2.4 2.1 2.6 <0.001
Geographical distribution
South-eastern Reference — — — Reference — — —
South-western 1.3 1.1 1.5 <0.001 1.3 1.1 1.5 <0.001
Other 1.2 1.02 1.5 0.03 1.3 1.1 1.5 0.01
RV vaccination
Unvaccinated Reference — — — Reference — — —
Vaccinated
Incomplete 0.4 0.2 0.7 0.001 0.4 0.3 0.8 0.004
Complete 0.2 0.1 0.3 <0.0001 0.2 0.1 0.3 <0.001
Severe gastroenteritis (Vesikari score  11) (n = 1277b)
Age in months
<6 Reference — — — Reference — — —
6–11 1.5 0.97 2.3 0.07 1.5 0.96 2.4 0.08
12–23 2.3 1.5 3.6 <0.001 2.3 1.5 3.7 <0.001
24–59 2.9 1.7 4.8 <0.001 2.7 1.6 4.6 <0.001
Sex
Male Reference — — — Reference — — —
Female 0.9 0.8 1.2 0.64 0.9 0.7 1.1 0.37
Admission year
2015 Reference — — — Reference — — —
2016 1.3 0.95 1.8 0.09 1.2 0.9 1.7 0.21
2017 1.0 0.7 1.4 1.00 0.9 0.6 1.2 0.34
2018 0.9 0.7 1.2 0.51 0.8 0.6 1.05 0.10
Seasonality
Rainy season (May–October) Reference — — — Reference — — —
Dry season (November–April) 2.0 1.6 2.5 <0.0001 2.0 1.6 2.5 <0.001
Geographical distribution
South-eastern Reference — — — Reference — — —
South-western (Mekong River Delta) 1.2 0.9 1.5 0.19 1.2 0.95 1.6 0.11
Other 1.3 0.9 1.9 0.17 1.3 0.9 1.9 0.16
RV vaccination
Unvaccinated Reference — — — Reference — — —
Vaccinated
Incomplete 0.1 0.02 1.2 0.07 0.3 0.03 2.3 0.23
Complete 0.2 0.1 0.4 <0.0001 0.2 0.1 0.4 <0.001
R, odds ratio; CI, confidence interval; ORS, oral rehydration solution; IV, intravenous; SD, standard deviation.
a Thirteen cases involving missing data were excluded from the analysis.
b Three cases involving missing data were excluded from the analysis.ortality in South-east Asian countries such as Myanmar, Laos and
hailand, regardless of RV vaccination coverage. In Vietnam, at the
ime of this study, RV vaccination was not included in the NIP, and
V vaccine coverage was low (3.9%). However, Vietnam experi-
nced consistent economic growth (an average annual increase of
.4% in GDP over the 6-year study period), which may have led to a28infection.
The major shift in genotype distribution from 2013 to 2018 is
notable. Currently, six major genotypes (G1P[8], G2P[4], G3P[8],
G4P[8], G9P[8] and G12P[8]) account for approximately 90% of all
human RV infections in many regions worldwide (Van Man et al.,
2001; Trang et al., 2014; Debellut et al., 2019). Until recently, G1P2
Table 3
Rotavirus genotypes in children with rotavirus (RV) gastroenteritis (n = 1105).
Total RV vaccine group Non-RV vaccine group
RV genotypes n (%) n (%) n (%) P-value
Single
All single genotypes 1086 100.0 16 100.0 1070 100.0
G3P[8] 478 43.1 5 31.3 473 43.4 0.30
G8P[8] 218 19.7 3 18.8 215 19.7 0.89
G1P[8] 143 12.9 4 25 139 12.8 0.16
G2P[4] 140 12.7 4 25 136 12.4 0.14
G9P[8] 38 3.4 0 0 38 3.5 —
G2P[8] 20 1.8 0 0 20 1.8 —
Othera 49 4.1 0 0 49 4.5 —
Combined
All combined genotypes 19 1.7 0 0 19 1.7 —
G1P[8]/G3P[8] 9 0.8 0 0 9 0.8 —
G1P[4]/G3P[4] 2 0.2 0 0 2 0.2 —
G2P[4]/G2P[8] 2 0.2 0 0 2 0.2 —
G1P[4]/G1P[8] 1 0.1 0 0 1 0.1 —
G3P[8]/G4P[8] 1 0.1 0 0 1 0.1 —
G1P[6]/G3P[8] 1 0.1 0 0 1 0.1 —
G8P[4]/G8P[10] 1 0.1 0 0 1 0.1 —
G8P[4]/G8P[8] 1 0.1 0 0 1 0.1 —
G9P[4]/G9P[8] 1 0.1 0 0 1 0.1 —
Total 1105 100.0 16 100.0 1089 100.0
Nt, non-typeable.
a Includes 11 G1P[4], nine G3P[4], five G3P[9], three G1P[6], three G4P[6], three GNtP[8], two G3P[6], two G3P[Nt], two G4P[8], two G9P[6], one G3P[11], one G5P[19], one
G8P[4], one G8P[6], one G9P[4], one G9P[Nt] and one undetermined case.
Figure 3. Vaccine effectiveness (VE) in hospitalized children with rotavirus (RV) gastroenteritis. The overall VE analysis included 4593 patients (>6 months of age) with RV-
vaccine-related information; 3376 patients with available RV genotype data were included in the genotyping analysis, and 4085 patients with available geographic data were
included in the geographic location analysis. (A) VEinpatientswhocompleted the vaccinationcourse regardlessof RV vaccinetype. (B) VE inpatientswhoreceived at leastone dose
of RV vaccine dose regardless of vaccine type. (C) VE in patients who completed the Rotarix vaccination course. (D) VE in patients who received at least one dose of Rotarix.
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merged as a predominant genotype in countries in Asia (Pakistan,
apan), South America (Argentina) and Europe (Germany, Spain)
Esposito et al., 2019). G3P[8] was the most prevalent genotype in
he present study, followed by G8P[8], G1P[8] and G2P[4]. A similar
enotype distribution was observed in studies conducted in
eighbouring ASEAN countries between 2010 and 2019 (Lestari
t al., 2020; Tacharoenmuang et al., 2020). In Thailand, where RV
accination was not included in the NIP until 2019, the prevalence
f G1P[8] (the most prevalent genotype) decreased while the
revalence of G3P[8] increased markedly between January 2014
nd September 2016 (World Health Organization, 2013a). More-
ver, the prevalence of infections caused by the G2P[4] genotype
as increased in children and adults in several countries using the
otarix vaccine (Tacharoenmuang et al., 2020). The increased
revalence of G3P[8] and G2P[4] can be attributed to the selective
ressure of RV vaccines, which appear to have lower VE against
hese genotypes (Van Man et al., 2001; Gupta et al., 2019;
olorunso and Sebolai, 2020). However, despite the fact that RV
accines had not been introduced into the NIP in Vietnam at the
ime of the study, the G2P[4] strain was the fourth most prevalent
enotype, and its prevalence fluctuated throughout the study
eriod. VE against G2P[4] has been reported to be lower than that
or other major genotypes, as observed in this study. Therefore,
ngoing surveillance of the dynamics of RV genotype, including the
2P[4] genotype, should continue after the introduction of RV
accine in the NIP.
The overall VE assessed in children hospitalized with RVGE
as 58.6–69.9% according to vaccination status. RV VE in other
tudies conducted in LMICs has ranged from 51% to 64%, which is
ower than that reported in high-income countries (85–98%) (Tu
t al., 2012; Pietsch and Liebert, 2019; Folorunso and Sebolai,
020). To date, three major RV vaccine studies have been
onducted in Vietnam. A phase 3 trial of RotaTeq reported VE
f 63.9% (Zaman et al., 2010). A trial of Rotarix found
eroconversion rates of 63.3–81.5% (Anh et al., 2011). A phase 2
rial of Rotavin-M1 found a seroconversion rate similar to that for
otarix (Anh et al., 2012). VE by genotype was only reported in the
otaTeq vaccine study. The seroconversion rate of G2 (9.9%) was
ower than the rates for G1 (32.1%), G3 (28.2%), G4 (18.3%) and
1A[8] (27.5%). The present study reported VE during a period
hen RV vaccination was only available in the private sector in
ietnam; the majority of those vaccinated received Rotarix. RV
accines have been shown to be effective, even in settings where
he vaccination rate is extremely low; however, VE varies by
enotype. VE against G2P[4] appears to be lower than VE for other
ajor genotypes. However, as there were only four cases of RVGE
ue to G2P[4] RV in the RV vaccine group, this result should be
nterpreted with caution.
This study has several limitations. First, it only included sentinel
urveillance data from southern Vietnam, which may not be
epresentative of the whole country. Second, as non-hospitalized
hildren were not included in the study, the results do not
epresent the epidemiology and genotype distribution in children
n the community. However, the population of southern Vietnam
ccounts for more than one-third of the total population of
ietnam, and this study was conducted on >5000 children
ospitalized with acute gastroenteritis. Finally, this study had
nsufficient statistical power to evaluate VE for some genotypes
ecause of the small number of children who had been vaccinated.
history was 58.6–69.9%. RV vaccines will soon be introduced into
the NIP in Vietnam, and continuous surveillance of RV genotypes is
essential to evaluate the effectiveness of the vaccination pro-
gramme.
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